TULIP ReTrain Study

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · May 8, 2025

Keywords

ClinConnect Summary

The TULIP ReTrain Study is a clinical trial looking to improve a computer program called the PCaVision AI, which helps doctors find and locate significant prostate cancer using special ultrasound technology. This study will test two different ultrasound contrast agents, Sonovue and Optison, to see how well they work in helping the AI detect cancer. Researchers will use a specific ultrasound machine to gather data from men who are having surgery to remove their prostate.

To be eligible for this study, participants must be men aged 18 and older who have been diagnosed with prostate cancer and are scheduled for surgery to remove their prostate. Another group of men with negative results from a specific type of prostate MRI may also participate. However, individuals with certain health issues, such as severe heart or lung conditions, or allergies to the contrast agents will not be able to join. While the trial is not yet recruiting, it aims to help improve cancer detection methods, which could benefit many patients in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male ≥18 years
• • Cohort 1: Histologically confirmed prostate cancer scheduled for radical prostatectomy
• • Cohort 2: Negative multiparametric prostate MRI (PI-RADS ≤ 2)
• Exclusion Criteria:
• • Severe pulmonary hypertension
• • Cardiac right-to-left shunt
• • Known allergy to Sonovue or Optison
• • Contraindication for ultrasound contrast agents